NewAmsterdam Pharma Company NV has published a document detailing the safety and efficacy of obicetrapib in patients at high cardiovascular risk. The document includes information on a study involving 2530 adult participants with heterozygous familial hypercholesterolemia and/or atherosclerotic cardiovascular disease. Key findings include the placebo-adjusted reduction in LDL-C with obicetrapib, which was 32.6% at day 84 and 24.0% at day 365. The full document can be accessed through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NewAmsterdam Pharma Company NV published the original content used to generate this news brief on June 06, 2025, and is solely responsible for the information contained therein.